Clinical Trials Logo

Cardiovascular Outcomes clinical trials

View clinical trials related to Cardiovascular Outcomes.

Filter by:
  • None
  • Page 1

NCT ID: NCT04125212 Active, not recruiting - Clinical trials for Cardiovascular Outcomes

Air Pollution and Cardio-metabolic Health

Start date: September 21, 2019
Phase:
Study type: Observational

To investigate the effects of air pollution on surrogate cardio-metabolic outcomes in young healthy adults.

NCT ID: NCT03899675 Completed - Clinical trials for Autonomic Nervous System

Impact of Caffeine Intake on Autonomic Parameters in the Exercise of Strength

Start date: December 19, 2018
Phase: N/A
Study type: Interventional

The objective of this study was to evaluate the variability of the heart rate of exercise physicists with and without caffeine intake. Practitioners of resisted physical exercise, specifically bodybuilding, who are young adults between the ages of 18 and 30 will participate in the study. To define the sample size, a sample calculation was performed based considering as variable the RMSSD index (square root of the square mean of the differences between the adjacent normal iRRs). The significant difference magnitude assumed was 12 ms, considering a standard deviation of 16.2 ms, with alpha risk of 5% and beta of 80%. A minimum of 14 subjects per group were required in the survey. A total of 32 subjects will participate in the research, being these divided and allocated in different groups. Sampling will be of the intentional kind.

NCT ID: NCT03206593 Recruiting - Clinical trials for Ischemic Heart Failure

Serum Lipids and Glucose Levels in Relation to CVD Outcomes in Patients With Ischemic Heart Failure

Start date: January 1, 2016
Phase: N/A
Study type: Observational [Patient Registry]

Current prospective cohort study is to evaluate the association between fasting lipid profiles (including total cholesterol, low density lipoprotein-cholesterol, high density lipoprotein-cholesterol, triglycerides, apolipoprotein A, apolipoprotein B and lipoprotein(a)) and fasting plasma glucose at admission with cardiovascular disease outcomes (including fatal and non-fatal myocardial infarction, fatal and non-fatal ischemic stroke, re-hospitalization due to heart failure, revascularization by percutaneous coronary intervention or coronary artery bypass grafting, or cardiovascular mortality) and all-cause mortality.in patients with ischemic heart failure and left ventricular ejection fraction < 45 % evaluated by echocardiography during 12 months follow-up.

NCT ID: NCT02601352 Completed - Clinical trials for Cardiovascular Outcomes

Air Pollution and Cardiometabolic Study

Start date: September 2015
Phase:
Study type: Observational

The study mainly focuse on examining the subjects living in traffic polluted area and assessing the popuation health risk using disease and risk assessment models.

NCT ID: NCT02058875 Withdrawn - Clinical trials for Cardiovascular Disease

Cardiovascular Risk Following Conversion to Full Dose Myfortic® and Neoral® Two-hour Post Level Monitoring

COBACAM
Start date: February 2014
Phase: Phase 4
Study type: Interventional

The overall goal of this study is to improve cardiovascular outcomes in transplant recipients. The current standard immunosuppressive regimen in kidney transplant recipients depends on a higher exposure to the Calcineurin Inhibitor (CNI), and often a less than optimal dosage the of mycophenolic acid (MPA) derivative. The premise of this study is to investigate the effects of reversing this paradigm. More specifically, the effect of using maximum MPA dosages (in the form of enteric-coated mycophenolate sodium [EC-MPS] or Myfortic®) along with judicious CNI exposure (cyclosporine/Neoral®) will be investigated.

NCT ID: NCT01921010 Completed - Clinical trials for Cardiovascular Outcomes

Benefit of Elevation of HDL-C in Women

Start date: June 2003
Phase: Phase 4
Study type: Interventional

The combination of HDL-C elevation, lowering of triglycerides and further LDL-C reduction accomplished by the addition of niacin to statin medication would improve endothelial function as compared to LDL-C reduction alone in patients with and without coronary artery disease and the combination of low HDL-C/high triglycerides. The combination of lipid lowering therapy would have beneficial effects on markers of inflammation. These benefits would be particularly evident in women.